SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
SEC Accession No. 0001072613-22-000148
Filing Date
2022-02-14
Accepted
2022-02-14 12:04:31
Documents
1
Group Members
ARCH VENTURE FUND IX OVERAGE, L.P.ARCH VENTURE PARTNERS IX OVERAGE, L.P.ARCH VENTURE PARTNERS IX, L.P.ARCH VENTURE PARTNERS IX, LLCCLINTON BYBEEKEITH CRANDELLROBERT NELSEN

Document Format Files

Seq Description Document Type Size
1 ARCH VENTURE FUND IX, L.P. - LYELL IMMUNOPHARMA -- SCH 13G arch-sch13g_18587.htm SC 13G 268524
  Complete submission text file 0001072613-22-000148.txt   270276
Mailing Address 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631
Business Address 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 773-380-6600
ARCH Venture Fund IX, L.P. (Filed by) CIK: 0001666306 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G

Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Subject) CIK: 0001806952 (see all company filings)

IRS No.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-93402 | Film No.: 22627825
SIC: 2834 Pharmaceutical Preparations